Compare Best Buy Co Inc (BBY) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Best Buy Co Inc vs Incyte Corporation — how do they compare? Best Buy Co Inc trades at $82.99 (market cap $17.55B), while Incyte Corporation trades at $120.65 (market cap $24.54B). The key difference: Incyte Corporation is the larger of the two by market cap, and Best Buy Co Inc pays a 4.61% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| BBY | INCY | |
|---|---|---|
Market Cap | $17.55B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.17 | $129.93 |
52-Week Low | $55.52 | $81.61 |
Enterprise Value | $19.93B | $20.04B |
Dividend Yield | 4.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBY trades at $83.24, up 0.98% on the day, near the consensus price target of $84.31. The stock shows a neutral technical signal with bullish moving averages. Recent earnings have consistently beaten estimates, and the company maintains solid profitability with a 39.1% ROE. Leadership changes, including a new CFO, and store format tests aim to drive future growth amid declining revenues.
The outlook is mixed: strong cash flow improvement and shareholder returns via dividends support upside, but revenue declines and competitive pressures pose risks. Analysts are cautious with a 'Hold' majority. Investors should weigh valuation attractiveness against execution challenges in a tough retail environment.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
